found that elevated expression of ASPM, TTK, and CDC20 conferred a poorer prognosis in breast cancer [9], and Jiang et al. identified six key genes (CA12, MLPH, FOXA1, GATA3, XBP1, and MAGED2) that could serve as biomarkers for the prediction of better chemotherapeutic responses and favorable prognosis in patients with breast cancer [10]. The gene discussed is FOXA1; the disease is breast carcinoma.